<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557024</url>
  </required_header>
  <id_info>
    <org_study_id>rfa-004</org_study_id>
    <nct_id>NCT00557024</nct_id>
  </id_info>
  <brief_title>Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma</brief_title>
  <acronym>RT-RFA</acronym>
  <official_title>Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the investigators study is to prospectively evaluate whether radiotherapy as
      an adjuvant therapy after RFA will improve the outcome of radiofrequency ablation for
      hepatocellular carcinoma (HCC) or not.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survivals</measure>
    <time_frame>3, abd 5-years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rates</measure>
    <time_frame>3-, and 5-years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>radiotherapy after RFA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RFA alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RFA</intervention_name>
    <description>radiofrequency ablation</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiotherapy after RFA</intervention_name>
    <description>radiotherapy after RFA</description>
    <arm_group_label>1</arm_group_label>
    <other_name>RT-RFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 75 years, who refused surgery

          -  A solitary HCC ≤ 7.0cm in diameter, or multiple HCC ≤ 3 lesions, each ≤ 3.0cm in
             diameter

          -  Lesions being visible on ultrasound (US) and with an acceptable/safe path between the
             lesion and the skin as shown on US,

          -  No extrahepatic metastasis

          -  No imaging evidence of invasion into the major portal/hepatic vein branches

          -  No history of encephalopathy, ascites refractory to diuretics or variceal bleeding

          -  A platelet count of &gt; 40,000/mm3

          -  No previous treatment of HCC except liver resection.

        Exclusion Criteria:

          -  Patient compliance is poor

          -  The blood supply of tumor lesions is absolutely poor or arterial-venous shunt that
             TACE can not be performed

          -  Previous or concurrent cancer that is distinct in primary site or histology from HCC,
             EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder
             tumors (Ta, Tis &amp; T1). Any cancer curatively treated &gt; 3 years prior to entry is
             permitted.

          -  History of cardiac disease:

               -  congestive heart failure &gt; New York Heart Association (NYHA) class 2;

               -  active coronary artery disease (myocardial infarction more than 6 months prior to
                  study entry is permitted);

               -  cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers,
                  calcium channel blocker or digoxin; or

               -  uncontrolled hypertension (failure of diastolic blood pressure to fall below 90
                  mmHg, despite the use of 3 antihypertensive drugs).

          -  Active clinically serious infections ( &gt; grade 2 National Cancer Institute
             [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Known Central Nervous System tumors including metastatic brain disease

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry

          -  Distantly extrahepatic metastasis

          -  History of organ allograft

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results

          -  Known or suspected allergy to the investigational agent or any agent given in
             association with this trial

          -  Any condition that is unstable or which could jeopardize the safety of the patient and
             his/her compliance in the study

          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a
             negative pregnancy test performed within seven days prior to the start of study drug.
             Both men and women enrolled in this trial must use adequate barrier birth control
             measures during the course of the trial.

          -  Excluded therapies and medications, previous and concomitant:

               -  Prior use of any systemic anti-cancer treatment for HCC, eg. chemotherapy,
                  immunotherapy or hormonal therapy (except that hormonal therapy for supportive
                  care is permitted). Antiviral treatment is allowed, however interferon therapy
                  must be stopped at least 4 weeks prior randomization.

               -  Prior use of systemic investigational agents for HCC

               -  Autologous bone marrow transplant or stem cell rescue within four months of start
                  of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>min-shan chen, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>min-shan chen, doctor</last_name>
    <phone>86-20-87343117</phone>
    <phone_ext>86-20-87343117</phone_ext>
    <email>Chminsh@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>min-shan chen, doctor</last_name>
      <phone>86-20-87343117</phone>
      <phone_ext>86-20-87343117</phone_ext>
      <email>Chminsh@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>min-shan chen, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg. 2002 Apr;235(4):466-86. Review.</citation>
    <PMID>11923602</PMID>
  </reference>
  <reference>
    <citation>Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8.</citation>
    <PMID>16495695</PMID>
  </reference>
  <reference>
    <citation>Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol. 2001;11(6):914-21.</citation>
    <PMID>11419162</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <last_update_submitted>November 17, 2008</last_update_submitted>
  <last_update_submitted_qc>November 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>cancer canter, Sun Yat-sen University</name_title>
    <organization>cancer canter, Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>liver cancer</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>adjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

